Drug Profile
CI 1015
Alternative Names: PD 145942Latest Information Update: 19 Jul 2002
Price :
$50
*
At a glance
- Originator Pfizer
- Class Anxiolytics
- Mechanism of Action Cholecystokinin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders
Most Recent Events
- 21 Jun 2000 Warner-Lambert has merged with Pfizer
- 11 Feb 1998 Preclinical development for Anxiety disorders in United Kingdom (Unknown route)